BACKGROUND: There is limited evidence that among HIV-infected patients haemoglobin A1c (HbA1c) values may not accurately reflect glycaemia. We assessed HbA1c discordance (observed HbA1c - expected HbA1c) and associated factors among HIV-infected participants in the Multicenter AIDS Cohort Study (MACS). METHODS: Fasting glucose (FG) and HbA1c were measured at each semi-annual MACS visit since 1999. All HIV-infected and HIV-uninfected men for whom at least one FG and HbA1c pair measurement was available were evaluated. Univariate median regression determined the association between HbA1c and FG by HIV serostatus. The relationship between HbA1c and FG in HIV-uninfected men was used to determine the expected HbA1c. Generalized estimating equations determined factors associated with the Hb1Ac discordance among HIV-infected men. Clinically significant discordance was defined as observed HbA1c - expected HbA1c ≤-0.5%. RESULTS: Over 13 years, 1500 HIV-uninfected and 1357 HIV-infected men were included, with a median of 11 visits for each participant. At an FG of 125 mg/dL, the median HbA1c among HIV-infected men was 0.21% lower than among HIV-uninfected men and the magnitude of this effect increased with FG >126 mg/dL. Sixty-three percent of HIV-infected men had at least one visit with clinically significant HbA1c discordance, which was independently associated with: low CD4 cell count (<500 cells/mm(3)); a regimen containing a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor or zidovudine; high mean corpuscular volume; and abnormal corpuscular haemoglobin. CONCLUSION: HbA1c underestimates glycaemia in HIV-infected patients and its use in patients with risk factors for HbA1c discordance may lead to under-diagnosis and to under-treatment of established diabetes mellitus.
BACKGROUND: There is limited evidence that among HIV-infectedpatients haemoglobin A1c (HbA1c) values may not accurately reflect glycaemia. We assessed HbA1c discordance (observed HbA1c - expected HbA1c) and associated factors among HIV-infectedparticipants in the Multicenter AIDS Cohort Study (MACS). METHODS: Fasting glucose (FG) and HbA1c were measured at each semi-annual MACS visit since 1999. All HIV-infected and HIV-uninfectedmen for whom at least one FG and HbA1c pair measurement was available were evaluated. Univariate median regression determined the association between HbA1c and FG by HIV serostatus. The relationship between HbA1c and FG in HIV-uninfectedmen was used to determine the expected HbA1c. Generalized estimating equations determined factors associated with the Hb1Ac discordance among HIV-infectedmen. Clinically significant discordance was defined as observed HbA1c - expected HbA1c ≤-0.5%. RESULTS: Over 13 years, 1500 HIV-uninfected and 1357 HIV-infectedmen were included, with a median of 11 visits for each participant. At an FG of 125 mg/dL, the median HbA1c among HIV-infectedmen was 0.21% lower than among HIV-uninfectedmen and the magnitude of this effect increased with FG >126 mg/dL. Sixty-three percent of HIV-infectedmen had at least one visit with clinically significant HbA1c discordance, which was independently associated with: low CD4 cell count (<500 cells/mm(3)); a regimen containing a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor or zidovudine; high mean corpuscular volume; and abnormal corpuscular haemoglobin. CONCLUSION: HbA1c underestimates glycaemia in HIV-infectedpatients and its use in patients with risk factors for HbA1c discordance may lead to under-diagnosis and to under-treatment of established diabetes mellitus.
Authors: Nancy A Hessol; Ann Kalinowski; Lorie Benning; Joanne Mullen; Mary Young; Frank Palella; Kathryn Anastos; Roger Detels; Mardge H Cohen Journal: Clin Infect Dis Date: 2006-12-12 Impact factor: 9.079
Authors: Marshall J Glesby; Donald R Hoover; Qiuhu Shi; Ann Danoff; Andrea Howard; Phyllis Tien; Dan Merenstein; Mardge Cohen; Elizabeth Golub; Jack Dehovitz; Marek Nowicki; Kathryn Anastos Journal: Antivir Ther Date: 2010
Authors: Todd T Brown; Stephen R Cole; Xiuhong Li; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: Arch Intern Med Date: 2005-05-23
Authors: Todd T Brown; Xiuhong Li; Stephen R Cole; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Joan S Chmiel; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Peter S Kim; Christian Woods; Patrick Georgoff; Dana Crum; Alice Rosenberg; Margo Smith; Colleen Hadigan Journal: Diabetes Care Date: 2009-06-05 Impact factor: 19.112
Authors: Michael Bergman; Muhammad Abdul-Ghani; João Sérgio Neves; Mariana P Monteiro; Jose Luiz Medina; Brenda Dorcely; Martin Buysschaert Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: James Muchira; Eileen Stuart-Shor; Jen Manne-Goehler; Janet Lo; Alexander C Tsai; Bernard Kakukire; Samson Okello; Mark J Siedner Journal: Int J STD AIDS Date: 2019-02-04 Impact factor: 1.359
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: Eric Zhang; Jin Choul Chai; Amy A Deik; Simin Hua; Anjali Sharma; Michael F Schneider; Deborah Gustafson; David B Hanna; Jordan E Lake; Leah H Rubin; Wendy S Post; Kathryn Anastos; Todd Brown; Clary B Clish; Robert C Kaplan; Qibin Qi Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 6.134
Authors: Kathleen A McGinnis; Amy C Justice; Sam Bailin; Melissa Wellons; Matthew Freiberg; John R Koethe Journal: Pharmacoepidemiol Drug Saf Date: 2020-10-01 Impact factor: 2.890